Amarin Announces Results of Annual General Meeting of Shareholders
22 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024...
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
15 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President &...
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
08 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic...
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
06 avr. 2024 15h30 HE
|
Amarin Corporation plc
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the...
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
03 avr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent...
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
25 mars 2024 08h00 HE
|
Amarin Corporation plc
-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 ...
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 févr. 2024 07h00 HE
|
Amarin Corporation plc
-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash...
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
15 févr. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President &...
Amarin Chairman & CEO Issue Letter to Shareholders
22 janv. 2024 07h30 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and...
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
10 janv. 2024 07h00 HE
|
Amarin Corporation plc
-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023 -- -- Company Ends 2023 with a Cash Position of $321 Million and Delivered Full-Year Positive...